Anticancer drug targets: cell cycle and checkpoint control
Open Access
- 15 December 1999
- journal article
- review article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 104 (12), 1645-1653
- https://doi.org/10.1172/jci9054
Abstract
No abstract availableThis publication has 42 references indexed in Scilit:
- UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independentOncogene, 1999
- Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1 and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicityOncogene, 1999
- Requirement for p53 and p21 to Sustain G 2 Arrest After DNA DamageScience, 1998
- p16INK4 Expression Is Associated with the Increased Sensitivity of Human Non‐small Cell Lung Cancer Cells to DNA Topoisomerase I InhibitorsJapanese Journal of Cancer Research, 1997
- A DNA Damage Checkpoint Meets the Cell Cycle EngineScience, 1997
- 7-Hydroxystaurosporine (UCN-01) Induces Apoptosis in Human Colon Carcinoma and Leukemia Cells Independently of p53Experimental Cell Research, 1997
- Chemical inhibitors of cyclin-dependent kinasesTrends in Cell Biology, 1996
- UCN-01: a Potent Abrogator of G2 Checkpoint Function in Cancer Cells With Disrupted p53JNCI Journal of the National Cancer Institute, 1996
- Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4.Genes & Development, 1996
- Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpointCell, 1995